Identifying subgroups deriving the most benefit from PD-1 checkpoint inhibition plus chemotherapy in advanced metastatic triple-negative breast cancer: a systematic review and meta-analysis

Abstract Background The combination of immunotherapy and chemotherapy has demonstrated an enhancement in progression-free survival (PFS) for individuals with advanced and metastatic triple-negative breast cancer (TNBC) when compared to the use of chemotherapy alone. Nevertheless, the extent to which...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Shengfa Lin, Bihe Fu, Muhammad Khan
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2024-12-01
Edice:	World Journal of Surgical Oncology
Témata:	Breast cancer Immunotherapy Immune checkpoint inhibitors (ICI) Pembrolizumab Atezolizumab Progression-free survival
On-line přístup:	https://doi.org/10.1186/s12957-024-03424-3
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!